Bioavailability Study of Two Prototype Fixed Dose Combination (FDC) Formulations of 10 mg Dapagliflozin and 1000 mg Metformin Extended Release (XR) Tablet Relative to Dapagliflozin 10 mg Tablet and Glucophage XR 2 X 500 mg Tablets Coadministered to Healthy Subjects in a Fasted State

Trial Profile

Bioavailability Study of Two Prototype Fixed Dose Combination (FDC) Formulations of 10 mg Dapagliflozin and 1000 mg Metformin Extended Release (XR) Tablet Relative to Dapagliflozin 10 mg Tablet and Glucophage XR 2 X 500 mg Tablets Coadministered to Healthy Subjects in a Fasted State

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Oct 2016

At a glance

  • Drugs Dapagliflozin/metformin (Primary) ; Dapagliflozin; Metformin
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors AstraZeneca; Bristol-Myers Squibb
  • Most Recent Events

    • 01 Apr 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 01 Apr 2010 Actual end date (Jan 2010) added as reported by ClinicalTrials.gov.
    • 01 Apr 2010 Actual patient number (15) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top